Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Isaac Ciechanover

Atara Biotherapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Marker Therapeutics, Inc.

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  

With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.  

Kleiner Perkins

Celgene

DAG Ventures

Domain Associates

EcoR1 Capital

Alexandria

Amgen Ventures

Atara Biotherapeutics

Today Atara announced the publication of the pivotal ALLELE tab-cel® study data in patients with relapsed or refractory Epstein-Barr virus (#EBV) positive post-transplant lymphoproliferative disease (#PTLD) in The Lancet Oncology, representing the first Phase 3 results published for an #allogeneic #Tcell therapy. 

➡Press release: https://bit.ly/4bkXbT1 

It was a pleasure highlighting the latest developments and potential of Atara's #allogeneic #CART programs for hematological malignancies and autoimmune diseases at #JPM24. https://bit.ly/3vxNksE

Next week, our CEO Pascal Touchon is heading to San Francisco to share Atara's latest pipeline progress & key development milestones at the J.P. Morgan Annual Healthcare Conference on Thursday, January 11 at 9:45 a.m. PT: https://bit.ly/3H8hXrd 

At this year's American Society of Hematology Annual Meeting, Atara will present positive preclinical data on ATA3431, our investigational next-generation #allogeneic CD20/CD19-targeted #CAR #EBV T-cell therapy for the treatment of B-cell malignancies. For more: https://bit.ly/3GA8b0O #ASH23  

Metric
Company Name	Atara Biotherapeutics, Inc.	Marker Therapeutics, Inc.
Symbol	ATRA	MRKR
MSH ID	COM:ATARABIO	COM:MARKERTHERAPEUTICS
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Grant
Employee Count	173	8
Website	atarabio.com	markertherapeutics.com
LinkedIn	atarabio	marker-therapeutics
Founders

Metric
Market Cap	44.24M	44.42M
Enterprise Value
Monthly Web Traffic	3.75K	4.75K
Web Traffic Growth	-0.55	-0.22
Valuation
Raised Capital		2M

Metric
Revenue	8.57M	3.31M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-313K	3.31M
EBITDA	-264.45M	-14.58M
Operating Income	-269.28M	-14.58M
Net Income	-276.13M	-16.97M
EPS	-2.61	-1.93
Diluted EPS	-2.61	-1.93
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.80	0.36
Operating Profit Margin	-2.68	-1.54
EBITDA Margin	-30.85	-4.40
Net Profit Margin	-2.90	-0.88
Return on Equity	20.16	-0.36
Return on Assets	-1.41	-0.40
Return on Capital Employed	14.32	-0.97

COM:ATARABIO

Atara Biotherapeutics Inc

Last Close

10.61

22/11 21:00

Market Cap

44.24M

Beta: -

Volume Today

65.66K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.42	-4.26
P/B Ratio	-2.42	2.38
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	19.51	15.58
EV Multiple	0.15	-2.73

Metric
Days Sales Outstanding	13.10	2.88
Days Payables Outstanding	415.04	249.06
Days Inventory Outstanding	552.47	0.00
Operating Cycle	1.85K	243.84
Cash Conversion Cycle	1.70K	243.84
Asset Turnover	0.53	0.54

Metric
Operating Cash Flow	-192.98M	-16.44M
Free Cash Flow	-194.20M	-16.44M
Cash Flow to Debt	-2.78	8.84
Operating Cash Flow/Sales	-2.11	-1.93
Free Cash Flow Yield	-1.34	-0.51

Metric
Cash & Equivalents	25.84M	15.11M
Accounts Receivable	6.11M	1.37M
Inventory	9.71M	1
Goodwill
Debt to Capitalization	5.64
Debt to Assets	0.33	-0.12
Current Ratio	1.50	7.01
Quick Ratio	1.30	6.32

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	10.31	0.14
R&D to Revenue	52.33	1.60
SG&A to Revenue	11.60	0.79